A Multi-Center Observational Study on the Use of Biologic Drugs as Monotherapy or Combination With DMARDs in Patients With Rheumatoid Arthritis in Italian Clinical Practice (ARMONIA)

Phase I: Number of Participants With Demographic Characteristics in Monotherapy and Combination Therapy

Phase I: Number of Participants With Disease Duration in Monotherapy and Combination Therapy

Phase I: Number of Participants With Comorbidity in Monotherapy and Combination Therapy

Phase I: Number of Participants With Autoantibody Status (Rheumatoid Factor and Anti-cyclic Citrullinated Protein Antibodies) in Monotherapy and Combination Therapy

Phase I: Number of Participants With Health Assessment Questionnaire- Disability Index in Monotherapy and Combination Therapy

Phase I: Number of Participants With Disease Activity Score 28 in Monotherapy and Combination Therapy

Phase I: Number of Participants With C-Reactive Protein Value and Erythrocyte Sedimentation Rate in Monotherapy and Combination Therapy

Phase I: Number of Participants With Clinical Disease Activity Index in Monotherapy and Combination Therapy

Phase I: Number of Participants With Simplified Disease Activity Index in Monotherapy and Combination Therapy

Phase I: Number of Participants With Duration of Combination Therapy Before Monotherapy in Monotherapy and Combination Therapy

Phase I: Number of Participants Treatment Line in Which Monotherapy Has Been Adopted in Monotherapy

Phase I: Number of Biologics Administered as Monotherapy in Monotherapy and Combination Therapy

Phase I: Number of Participants With Prevalence of Previous Therapy Switches and Swaps in Monotherapy and Combination Therapy

Phase I: Number of Participants With Reasons Leading to the Use of Biologic in Monotherapy

Phase II: Percentage of Participants Who Retained on Tocilizumab Monotherapy

Phase II: Retention Rate in Therapy, Percentage of Participants Achieving DAS 28 ESR <2.6 and <3.2 at Month 18

Phase I: Median Disease Duration in Monotherapy and Combination Therapy

Phase I: Percentage of Participants With Comorbidity in Monotherapy and Combination Therapy

Phase I: Mean Health Assessment Questionnaire-Disability Index in Monotherapy and Combination Therapy

Phase I: Percentage of Participants Who Started Treatment With a Biologic Drug in Monotherapy and Percentage of Participants Who Stopped a DMARDs While Taking a Biologic Drug in Combination Therapy

Phase I: Number of Participants Receiving a Biologic Drug as Monotherapy at Different Treatment Lines

Phase I: Number of Participants With at Least One Previous Treatment With Biologics Drug as a Monotherapy in Monotherapy and Combination Therapy

Phase I: Percentage of Participants With Prevalence of Previous Therapy Switches and Swaps in Monotherapy and Combination Therapy

Phase I: Median DAS28 at Study Entry in Monotherapy and Combination Therapy

Phase I: Number of Participants With CDAI Scores at Study Entry in Monotherapy and Combination Therapy

Phase I: Number of Participants With SDAI Scores at Study Entry in Monotherapy and Combination Therapy

Phase I: Mean Tender Joints and Swollen Joints as Disease Activity at Study Entry in Monotherapy and Combination Therapy

Phase I: Percentage of Participants Treated With Corticosteroids at Study Entry in Monotherapy and Combination Therapy

Phase I: Mean Dose of Corticosteroids At Study Entry in Monotherapy and Combination Therapy

Phase I: Mean Duration of Previous Treatment With a Biologic Drug in Monotherapy and Combination Therapy

Phase I: Mean Duration of Treatment With A Biologic Drug in Combination With DMARDs Before Monotherapy

Phase II: Percentage of Participants Maintaining Delta DAS 28 CRP of >= 0.6 at Months 3, 6, 12, and 18

Phase II: Percentage of Participants Maintaining Delta DAS28 ESR >= 0.6 at Months 3, 6, 12, and 18

Phase II: Percentage of Participants Achieving DAS28 CRP Remission (< 2.6) and Low Disease Activity (<3.2) at Months 3, 6, 12, and 18

Phase II: Percentage of Participants Achieving DAS 28 ESR (< 2.6) and Low Disease Activity (<3.2) at Months 3, 6, 12, and 18

Phase II: Percentage of Participants Achieving CDAI Remission (< 2.8) at Months 3, 6, 12, and 18

Phase II: Percentage of Participant Achieving SDAI Remission (< 3.3) at Months 3, 6, 12, and 18

Phase II: Mean Change From Baseline in TJC And SJC at Months 3, 6, 12, and 18

Phase II: Mean Change From Baseline in Dose of Corticosteroids at Months 3, 6, 12, and 18

Phase II: Percentage of Participants With Delta HAQ >= 0.21 at Months 3, 6, 12, and 18

Phase II: Mean VAS Fatigue Score Overtime

Phase II: Number of Participants With Any Adverse Events, Any Serious Adverse Events, Adverse Events of Special Interest, and Tubercular Events

Phase II: Number of Participants With Retention in Therapy Without Interruption Due to Side Effects

Phase II: Number of Side Effects That Had Not Induced Discontinuation of Treatment

Phase II: Number of Side Effects That Induced Transient Interruption of Treatment

Phase II: Mean Change From Baseline in Hemoglobin Levels Over Time

Phase II: Mean Change From Baseline in Hematocrit, Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes Over Time

Phase II: Mean Change From Baseline in Red Blood Cells, White Blood Cells, and Platelets Over Time

Phase II: Mean Change From Baseline in Total Cholesterol, Low-density and High-density Lipoprotein Cholesterol, Triglycerides, Total Bilirubin, Direct Bilirubin, Glucose, Creatinine, Blood Urea Nitrogen Levels Over Time

Phase II: Mean Change From Baseline in Aspartate Transaminase, Alanine Transaminase, Gamma-glutamyl Transpeptidase, and Alkaline Phosphatase Levels Over Time

Phase II: Mean Change From Baseline in Serum Electrophoresis Parameters Over Time